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Abstract
Background:  The apolipoprotein E (APOE) and tau proteins play important roles in the
pathological development of Alzheimer's disease (AD). Many studies have shown an association
between the APOE gene and AD. Association between AD and the newly discovered saitohin (STH)
gene, nested within the intron of the tau gene, has been reported. The present study aimed to
elucidate the association between APOE and AD, and between STH and AD in our sample.
Methods: The functional polymorphisms, rs429358 and rs7412, in the APOE gene (which together
define the ε2, ε3, and ε4 alleles), and the Q7R SNP in the STH gene, were genotyped in 369 patients
with AD and 289 healthy European-Americans. The associations between these two genes and AD
were analyzed in a case-control design.
Results: Consistent with previously reported results, the frequencies of the APOE ε4 allele, ε4/ε4
genotype and ε3/ε4 genotype were significantly higher in AD cases than controls; the ε4/ε4
genotype frequency was significantly higher in early-onset AD (EOAD) than late-onset AD
(LOAD); the frequencies of the ε2 allele, ε3 allele, ε3/ε3 genotype and ε2/ε3 genotype were
significantly lower in AD cases than controls. Positive likelihood ratios (LRs+) of APOE alleles and
genotypes increased in a linear trend with the number of ε4 alleles and decreased in a linear trend
with the number of ε2 or ε3 alleles. There was no significant difference in the STH allele and
genotype frequency distributions between AD cases and controls.
Conclusion: This study confirmed that the ε4 allele is a dose-response risk factor for AD and the
ε4/ε4 genotype was associated with a significantly earlier age of onset. Moreover, we found that
the ε2 allele was a dose-response protective factor for AD and the ε3 allele exerted a weaker dose-
response protective effect for risk of AD compared with ε2. In a clinical setting, APOE genotyping
could offer additional biological evidence of whether a subject may develop AD, but it is not robust
enough to serve as an independent screening or predictive test in the diagnosis of AD. STH
variation was not significantly associated with AD in our sample.
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Background
Alzheimer's disease (AD) is the most common cause of
dementia. It is a primary neurodegenerative cerebral dis-
ease in the elderly, characterized by two major his-
topathologic changes in the brain, i.e., extracellular
amyloid plaques and intracellular neurofibrillary tangles
[1,2].
Apolipoprotein E (APOE) is one of the major cholesterol
transport proteins. It exists in three major isoforms,
APOE2, APOE3 and APOE4. The three APOE isoforms dif-
fer in the 112th and 158th residues of their primary struc-
tures (Figure 1); these differences are classified as SNPs
rs429358 and rs7412, respectively. The APOE3 protein
has higher receptor affinity than the variant types APOE2
and APOE4. Substitution of the basic amino acid Arg158
in APOE3 by the neutral amino acid Cys158 in APOE2
results in the receptor affinity of APOE2 being reduced to
2% of that of APOE3 [3]. In the central nervous system,
APOE mediates the uptake and redistribution of choles-
terol, and different APOE isoforms modify cholesterol
homeostasis by preferentially associating with specific
lipoprotein particles [4]. The role of APOE in modifying
cholesterol homeostasis in the brain may contribute to
the relationship between APOE and AD. Furthermore,
APOE exists inside the amyloid plaque, where it can bind
to β-amyloid (Aβ), which is a major component of the
plaque [5]. Studies have shown that APOE interacts with
Aβ to form a stable complex, altering the deposition of Aβ
and affecting Aβ-induced neurotoxicity [6].
Moreover, APOE may be involved in Alzheimer's disease
through a tau pathway. Studies have indicated that tau
plays an important role in the physiopathology of Alzhe-
imer's disease and that an extended haplotype (H1), cov-
ering the entire tau gene, including a 238 bp insertion in
intron 9, is associated with AD [2,7-12], although these
observations have not always been confirmed by other
studies. APOE2 and APOE3 can bind to tau and prevent
tau from being hyperphosphorylated. Although APOE4
also binds to tau, it cannot prevent tau from hyperphos-
phorylation, but destabilizes tau. The hyperphosphor-
ylated tau can decrease tau's affinity for microtubules and
severely disrupt microtubule stability, which has been
postulated to be an important step in the formation of the
paired helical filament (PHF) involved in neuronal degen-
eration. This may be part of the mechanism of APOE's
important role in the etiology of AD.
APOE2, APOE3 and APOE4 are encoded by the ε2, ε3 and
ε4 alleles, respectively [13]. The roles of these alleles in
modulating risk for AD have been widely studied. (a) The
ε4 allele contributes to the risk for AD across most popu-
lations [e.g., [14,15]]. (b) AD patients with the ε4 allele
have an earlier age-of-onset than those without the ε4
allele [e.g., [16,17]]. (c) The ε4 allele has a significant dose
effect on the risk for AD [e.g., [18-20]]. (d) The ε2 allele
may protect individuals from being affected with AD [e.g.,
[14,15]].
HhaI cleavage sites within the APOE amplicon Figure 1
HhaI cleavage sites within the APOE amplicon. 1 The residue positions are updated in the NCBI SNP database http://
www.ncbi.nlm.nih.gov/SNP/. ε2 allele (haplotype): 130Cys+176Cys (old:112Cys+158Cys) = 91bp+83 bp+others (≤ 33 bp); ε3 
allele (haplotype): 130Cys+176Arg (old:112Cys+158Arg) = 91 bp+ 48 bp+35 bp+others (≤ 33 bp); ε4 allele (haplotype): 
130Arg+176Arg (old:112Arg+ 158Arg) = 72+48+35+19+others (≤ 33 bp).
Length (bp)                                 |19+72=91|    |48+35=83| 
HhaI cleavage sites  0       33   49   68            140 158       206     241 248 259 272     303 
                             |------|----|----|-----------|---|--------|-------|----|----|----|------|
New residue positions
1          118  124   130                                    176 
Old residue positions                             112                                    158 
Nucleotide substitution                          T/C                                   T/C 
Amino acid substitution                     Cys/Arg                            Cys/Arg 
NCBI database Rs#                           rs429358                             rs7412 Behavioral and Brain Functions 2006, 2:13 http://www.behavioralandbrainfunctions.com/content/2/1/13
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Saitohin (STH), an intronless gene, has been shown to be
nested in the intron between exons 9 and 10 of the tau
gene, 2.5 kb downstream from exon 9. This region is func-
tionally critical due to the splicing of exon 10. The special
location of the STH gene has prompted investigation into
its possible role in AD and other neurodegenerative disor-
ders. The A224G polymorphism in the STH gene, which
causes a glutamine (Q) to arginine (R) substitution at res-
idue 7 (Q7R), is in linkage disequilibrium with the
extended tau H1/H2 haplotype [21,22]. That is, the STH
Q allele is associated with tau haplotype H1, and the STH
R allele is associated with haplotype H2. An initial study
by Conrad et al. [23] demonstrated that the Q7R poly-
morphism in the STH gene was associated with risk for
AD. The STH gene has also been associated with auto-
somal dominant frontotemporal dementia (FTD), pro-
gressive supranuclear palsy (PSP) and Pick's disease
[21,23-25]. Nevertheless, these findings remain contro-
versial [22,25-29].
The purpose of the present study was to elucidate the asso-
ciations between the variants at APOE and STH loci and
AD in our samples, and to explore the gene-dose effects
and evaluate the implications of variation at the APOE
gene in the diagnosis of AD.
Methods and materials
Subjects
The sample included 658 European-Americans, including
369 patients with AD and 289 healthy controls. The diag-
nosis of AD was based on criteria of the National Institute
of Neurological and Communicative Disorders and
Stroke and Alzheimer's disease and Related Disorders
Association (NINCDS-ADRDA) [30]. The AD cases were
divided into an early-onset (EOAD) group and a late-
onset (LOAD) group based on an age-of-onset of 70 years
[27,29]. Each subject was evaluated for an approximate
date of AD onset, based on careful review of medical
records and detailed interviews with one or more primary
caregivers. The date of onset was operationally defined as
the date at which the "earliest definite AD symptom"
appeared. The mean age of AD patients was 73.6± 8.4
years (range: 51.8 to 92.7); the mean age-of-onset was
69.3± 8.3 years (range: 44.6 to 86.7; 3 subjects unknown);
143 were male, 226 were female; 180 had positive family
history (FH+), 184 had negative family history (FH-), and
5 had unknown family history. Family history of AD was
assessed using the Alzheimer Dementia Risk Question-
naire (ADRQ) [31] and the Dementia Questionnaire
(DQ) [32]. Family history was considered positive if at
least one first-degree relative met criteria for primary
degenerative dementia. No cases suggestive of autosomal
dominant transmission were identified.
There were two sets of control subjects who were differen-
tiated based on the method of ascertainment. The first set
of healthy controls (n = 185) was recruited through adver-
tisements in the community. They were screened using the
Structured Clinical Interview for DSM-III-R (SCID), the
Computerized Diagnostic Interview Schedule for DSM-
III-R (C-DIS-R), the Schedule for Affective Disorders and
Schizophrenia (SADS) [33], or an unstructured interview,
to exclude major Axis I disorders, including substance
dependence, psychotic disorders, mood disorders, anxiety
disorders and dementia. Their mean age was 28.1± 9.1
years (range: 18.0 to 52.0); 81 were male and 104 were
female. The second set of healthy controls (n = 104) was
recruited primarily from among spouses of AD patients.
Their mean age was 63.3± 16.3 years (range: 21.1 to 87.5);
49 were male and 55 were female. They were evaluated as
being in generally good medical health for their age on the
basis of a comprehensive evaluation that included medi-
cal history, physical and neurological examinations,
serum chemistries, thyroid function studies, complete
blood count, B12, folate, VDRL, urinalysis, electrocardio-
gram, and brain MRI or CT. The second set of controls was
also required to have no significant evidence of cognitive
impairment, as indicated by a Mini-Mental State Exami-
nation (MMSE) [34] score > 27. Subjects were recruited at
Yale University School of Medicine, the University of
Connecticut Health Center, or the VA Connecticut
Healthcare System, West Haven Campus. Informed con-
sent was obtained from all the patients and the controls.
This study was performed after approval by the appropri-
ate Institutional Review Boards (IRBs).
Genotyping
Genomic DNA was extracted from peripheral blood by
standard methods. The region flanking the two target
markers within exon 5 of APOE, rs429358 and rs7412,
was amplified by a single polymerase chain reaction
(PCR) using the following primers [35]: APOE-A: 5'-
CGGGCACGGCTGTCCAAGGAG-3' and APOE-C: 5'-
CACGCGGCCCTGTTCCACgAG-3' (g is mismatched).
PCR was performed in a final volume of 10 μl with 1× PC2
buffer (Ab Peptides, Inc., St. Louis, MO), 1M betaine, 0.5
units of KlenTaq polymerase (Ab Peptides, Inc., St. Louis,
MO) and 10 ng DNA. PCR conditions were set as follows:
95°C for 5 min; 35 cycles of 95°C for 30 s, 64°C for 30 s,
and 72°C for 30 s. The genotypes were analyzed on 5%
metaphor agarose gel after digestion with HhaI (New Eng-
land Biolabs Inc., Beverly, MA). The size of the PCR prod-
uct was 303 bp, within which there are eight constant
HhaI cleavage sites (GCG|C) and two variant HhaI cleav-
age sites (see Figure 1).
The region flanking the Q7R marker in the STH gene was
amplified by PCR using the primers from the initial study
by Conrad et al. [23]. PCR was performed in a final vol-Behavioral and Brain Functions 2006, 2:13 http://www.behavioralandbrainfunctions.com/content/2/1/13
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ume of 15 μl with 1× PC2 buffer, 1M betaine, 0.75 units
of KlenTaq polymerase and 25 ng DNA. PCR conditions
were set as follows: 95°C for 5 min; 30 cycles of 95°C for
30 s, 60°C for 30 s, and 72°C for 30 s. The genotypes were
analyzed on 3% metaphor agarose gel after digestion with
HinfI (New England Biolabs Inc., Beverly, MA). The size of
the PCR product was 226 bp. The R allele (Arginine, CGA)
can be cut by HinfI (97 bp+74 bp+55 bp), whereas the Q
allele (Glutamine, CAA) cannot (171 bp+55 bp).
Statistical analysis
The comparisons in allele and genotype frequency distri-
butions between two groups were performed with Fisher's
exact test. Bonferroni correction was used to adjust the α
level of multiple comparisons [36].
Positive predictive values (PPVs) were calculated with
Bayes' rule [37]. P(AD) was the prior probability of devel-
oping AD, i.e., the prevalence of AD (see Formula). We
used 15% as the estimated prevalence of AD [38]; P(Con-
trols) ≈ 1-P(AD); P(ε|AD) was allele or genotype frequency
in AD cases, and P(ε|Controls) was allele or genotype fre-
quency in controls. Both P(ε|AD) and P(ε|Controls) were
estimated from the present study;   (AD|ε) was the pos-
terior probability of developing AD given a certain allele
or genotype.
Positive likelihood ratios (LRs+) were calculated by divid-
ing the allele or genotype frequencies in AD cases by those
in controls [39]. For example, if the frequency of the ε4/ε4
genotype is 0.139 in AD cases and 0.037 in controls, then
the LR+ is equal to 0.139/0.037 = 3.757.
The dose effect of the APOE gene, i.e., the relationship
between the risk for AD and the number of APOE alleles,
was tested by the chi-square test for trend using the soft-
ware EPISTAT [40]. The relationships between the
number of APOE alleles and their LRs+ were tested with
Spearman's rank correlation analysis implemented in
SPSS 13.0 (SPSS Inc., Chicago, IL). Gene dose effects for
APOE were plotted using a polynomial curve-fitting plot
method in S-PLUS 2000 (Mathsoft Engineering & Educa-
tion, Inc., Cambridge, MA).
Age, sex, and AD family history are confounders that may
cause false positive or false negative results. Thus, we used
stepwise logistic regression analysis to investigate the
association between the risk for AD and the number of
APOE and STH alleles, controlling for the effects of the
potential confounders. In the stepwise logistic regression
model, the diagnosis served as the dependent variable; the
independent variables included the number of APOE ε4
alleles, the number of APOE ε2 alleles, the number of STH
R alleles, the interaction between STH R allele and APOE
alleles, age, sex and AD family history. This analysis was
performed with SPSS 13.0 software.
Results
There was no significant difference in allele frequency dis-
tributions, genotype frequency distributions or dose
effects of APOE and STH gene between our two sets of
controls, so we combined the two control groups into one
larger control group.
Associations of APOE alleles and genotypes with 
Alzheimer's disease
The comparisons of allele and genotype frequency distri-
butions between AD cases and controls are shown in
Tables 1 and 2. The genotype frequency distributions in
both AD cases and controls were in Hardy-Weinberg equi-
librium (HWE).
The overall allele and genotype frequency distributions in
AD cases were significantly different from those in con-
trols. The frequencies of the ε4 allele, ε3/ε4 and ε4/ε4 gen-
otypes were significantly higher in AD cases than in
controls and the frequencies of the ε2, ε3 alleles, ε2/ε3
and ε3/ε3 genotypes were significantly lower in AD cases
than in controls.
We also compared allele and genotype frequencies in AD
subgroups (EOAD, LOAD, FH+ AD, FH- AD, male AD and
female AD) with those in controls. The overall allele and
genotype frequency distribution in each of the AD sub-
groups was significantly different from that in controls.
Specifically, the frequencies of the ε4 allele and the ε3/ε4
genotype in each of the AD subgroups, and the ε4/ε4 gen-
otype in EOAD, FH+ AD, FH- AD, and female AD were sig-
nificantly higher than those in controls; the frequencies of
the ε3 allele and the ε3/ε3 genotype in each of the AD sub-
groups, and the ε2 allele in EOAD, FH+ AD and female AD
were significantly lower than those in controls. The geno-
type frequency distributions were significantly different
between EOAD and LOAD [(the ε4/ε4 genotype fre-
quency in EOAD (0.203) was significantly higher than
that in LOAD (= 0.082)]. Among these differences, the
nominal difference in the frequency of the ε2 allele
between cases and controls was not statistically significant
after Bonferroni correction.
Stepwise logistic regression analyses showed that after
adjusting for age, sex, and AD family history, the ε4 and
ε2 alleles were still significantly associated with risk for
AD (Pε4 = 0.014, adjusted ORε4 = 1.86,95% Clε4: 1.13–
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Table 2: Distributions of the genotype frequencies of the APOE gene variations in European-American subjects
APOE genotypes Exact P-values
ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4T o t a l ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4T o t a l
f N f N f N f N f NN
AD 0.036 13 0.011 4 0.384 138 0.429 154 0.139 50 359 0.001 0.721 8.1*10-11 3.0*10-10 1.9*10-5 2.1*10-16
EOAD 0.029 5 0.006 1 0.390 67 0.372 64 0.203 35 172 0.004 0.653 1.1*10-7 2.9*10-5 5.8*10-8 2.5*10-13
LOAD 0.038 7 0.016 3 0.386 71 0.478 88 0.082 15 184 0.010 1.000 3.8*10-8 1.6*10-10 0.056 2.5*10-11
FH+ 0.029 5 0.000 0 0.341 59 0.468 81 0.162 28 173 0.004 0.146 2.8*10-10 9.8*10-10 1.4*10-5 4.1*10-16
FH- 0.039 7 0.022 4 0.425 77 0.392 71 0.122 22 181 0.010 0.727 3.3*10-6 3.5*10-6 0.001 6.1*10-9
Male 0.043 6 0.021 3 0.390 55 0.447 63 0.099 14 141 0.053 1.000 1.8*10-5 1.8*10-6 0.099 6.3*10-7
Female 0.032 7 0.005 1 0.381 83 0.417 91 0.165 36 218 0.015 0.559 1.7*10-6 6.4*10-5 8.7*10-5 8.9*10-10
EOAD vs. LOAD 0.772 0.624 1.000 0.053 0.001 0.009
Controls 0.106 26 0.016 4 0.654 161 0.187 46 0.037 9 246
Male 0.113 13 0.017 2 0.661 76 0.165 19 0.043 5 115
Female 0.099 13 0.015 2 0.649 85 0.206 27 0.031 4 131
f, N, AD, EOAD, LOAD, Controls and the comparing methods see Table 1. EOAD vs. LOAD, comparing EOAD and LOAD. α was set at 0.010 (or 0.002) for each genotype comparison between overall AD and 
controls (or between AD subgroups and controls), referring to Table 1. ε2/ε3, the genotype consists of allele ε2 and allele ε3; as analogy.
Table 1: Distributions of allele frequencies of APOE and STH gene variations in European-American subjects
APOE alleles Exact p-values STH alleles Exact p-values
ε2 ε3 ε4T o t a l ε2 ε3 ε4T o t a l Q RT o t a l
f n f n f n2 N f n f n2 N
AD 0.024 17 0.617 443 0.359 258 718 0.001 6.0*10-12 2.4*10-18 1.2*10-18 0.767 439 0.233 133 572 0.345 1
EOAD 0.017 6 0.590 203 0.392 135 344 0.002 4.7*10-11 6.8*10-17 2.5*10-17 0.771 216 0.229 64 280 0.506 2
LOAD 0.027 10 0.644 237 0.329 121 368 0.022 3.6*10-7 3.1*10-11 5.5*10-11 0.762 218 0.238 68 286 0.348 2
FH+ 0.014 5 0.590 204 0.396 137 346 6.8*10-4 4.9*10-11 2.1*10-16 2.3*10-17 0.737 205 0.263 73 278 0.094 2
FH- 0.030 11 0.641 232 0.329 119 362 0.051 2.2*10-7 4.1*10-11 1.1*10-10 0.796 226 0.204 58 284 1.000 2
Male 0.032 9 0.635 179 0.333 94 282 0.093 3.9*10-5 1.7*10-7 3.9*10-7 0.738 155 0.262 55 210 0.145 3
Female 0.018 8 0.606 264 0.376 164 436 0.008 7.0*10-8 9.8*10-12 4.9*10-12 0.785 284 0.215 78 362 1.000 3
Controls 0.061 30 0.801 394 0.138 68 492 0.794 313 0.206 81 394
Male 0.065 15 0.800 184 0.135 31 230 0.805 140 0.195 34 174
Female 0.057 15 0.802 210 0.141 37 262 0.786 173 0.214 47 220
f, frequency; n, number of alleles; N, number of individuals; 2N, number of chromosomes; AD, Alzheimer's disease; EOAD, early-onset AD (≤70yrs); LOAD, late-onset AD (>70yrs); Controls, the total controls 
combining two subgroups through two different diagnostic evaluations. The numbers in last column denote: 1. Comparing overall AD with controls (α was set at 0.017 for each APOE allele comparison); 2. 
Comparing EOAD, LOAD, FH+AD and FH-AD with controls respectively (α was set at 0.003 for each APOE allele comparison); 3. Comparing male AD with male controls and female AD with female controls (α was 
set at 0.003 for each APOE allele comparison).Behavioral and Brain Functions 2006, 2:13 http://www.behavioralandbrainfunctions.com/content/2/1/13
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3.05; Pε2 = 0.041, adjusted ORε2 = 0.36,95% Clε2:0.13–
0.96).
PPVs and LRs+ of the APOE gene for the diagnosis of AD
PPVs and LRs+ of APOE alleles and genotypes for AD are
listed in Table 3. Both PPVs and LRs+ of APOE alleles and
genotypes were in the following order: ε4/ε4 > ε4 > ε3/ε4
> ε3 > ε2/ε4 > ε3/ε3 > ε2 > ε2/ε3.
We also compared PPVs for different subtypes of AD. PPVs
of the ε4/ε4 genotype were much higher in EOAD (49.2%
vs. 28.1% for LOAD), female AD (48.4% vs. 28.9% for
male AD) and FH+ AD (43.6% vs. 36.8% for FH- AD). In
addition, the PPV for the ε3/ε4 genotype was higher in
LOAD (31.1%) than EOAD (26.0%). Finally, the PPVs
were lower for FH+ AD for the ε2 allele and the ε2/ε3 gen-
otype (3.9%, 4.6%, respectively) than for FH- AD (8.0%,
6.1%, respectively).
Gene dose effects of the APOE gene on the risk for AD 
(Table 4 and Figure 2)
The chi-square test for trend analyses showed that there
was a significant positive correlation between the number
of ε4 alleles and risk for AD and a significant negative cor-
relation between the number of ε2 or ε3 alleles and risk
for AD.
Similarly, the Spearman's rank correlation analysis
showed that the number of APOE alleles was significantly
correlated with LR+, which increased linearly with the
number of the ε4 alleles (correlation coefficient rε4 = 1.0;
slope K ε4  = 1.602) and decreased linearly with the
number of ε2 or ε3 alleles (correlation coefficient rε2 or ε3 =
1.0; slope Kε2 = -0.543; slope Kε3 = -1.122).
Association of the STH gene with AD
No significant difference in STH allele and genotype fre-
quency distributions was found between AD cases and
controls. Even after adjusting for potential confounding
by the APOE gene, age, sex and AD family history, step-
wise logistic analyses showed no association of STH alle-
les or genotypes with AD.
Interactive effects between the STH gene and the APOE 
gene
Using STH genotypes, we grouped all subjects into QQ,
RR and QR groups. We then compared APOE allele and
genotype frequency distributions in these three groups in
both cases and controls. No significant difference was
found for any of the comparisons (data not shown).
Discussion
The present study confirmed the well-established associa-
tion between the APOE gene and AD. All three APOE alle-
les (ε2, ε3 and ε4) showed dose effects on the risk for AD,
and followed a co-dominant mode of inheritance. We
also examined, for the first time to our knowledge for a
trait in neuropsychiatry, a mathematical measure of the
predictive value of each APOE allele and genotype for AD
diagnosis risk.
In addition to a significant association between the APOE
gene and Alzheimer's disease, subgroup analyses revealed
an association with subtypes based on age of onset, family
history, and sex. The ε4 allele, the ε4/ε4 genotype and the
ε3/ε4 genotype were risk factors for AD; the ε2 allele, the
ε3 allele, the ε2/ε3 genotype and the ε3/ε3 genotype were
protective factors for AD. These findings are consistent
with those in most previous studies [e.g., [14,15]]. Further
comparisons among AD subgroups and controls showed
Table 3: Interpretation of PPVs and LRs+ of APOE alleles and genotypes
allele/genotype
PPV [  (AD|ε)]
LR+ LR range1 Significance for diagnosis
> 10 greatly increasing risk for AD
5~ 10 moderately increasing risk for AD
ε4/ε4 39.90% 3.76 2~ 5 small increase in risk for AD
ε4 31.50% 2.60
ε3/ε4 28.80% 2.29
1~ 2 minimally increasing risk for AD
15.00% (population prevalence) 1 no change in risk for AD
ε3 12.00% 0.77 0.5~ 1 minimally decreasing risk for AD
ε2/ε4 10.82% 0.69
ε3/ε3 9.40% 0.59
ε2 6.50% 0.39 0.2~ 0.5 small decrease in risk for AD
ε2/ε3 5.70% 0.34
0.1~ 0.2 moderately decreasing risk for AD
< 0.1 greatly decreasing risk for AD
PPV, estimated positive predictive value; LR+, positive likelihood ratios.
1Reference to [39].
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Table 4: Distributions of the frequencies of the genotypes with ascending APOE allele number
Number of ε2 alleles Chi-Square test for trend Number of ε3 alleles Chi-Square test for trend Number of ε4 alleles Chi-Square test for trend
01 2 χ2 P012 χ2 P0 1 2 χ2 P
f N f N f N f N f N f N f N f N f N
AD 0.953 342 0.047 17 0 0 11.32 0.001 0.150 54 0.465 167 0.384 138 43.02 < 0.0001 0.421 151 0.440 158 0.139 50 < 0.0001
EOAD 0.965 166 0.035 6 0 0 9.73 0.002 0.209 36 0.401 69 0.390 67 37.41 < 0.0001 0.419 72 0.378 65 0.203 35 56.72 < 0.0001
LOAD 0.946 174 0.054 10 0 0 5.69 0.017 0.098 18 0.516 95 0.386 71 26.27 < 0.0001 0.424 78 0.494 91 0.082 15 42.63 < 0.0001
FH+ 0.971 168 0.029 5 0 0 11.46 0.001 0.162 28 0.497 86 0.341 59 41.06 < 0.0001 0.370 64 0.468 81 0.162 28 61.13 < 0.0001
FH- 0.939 170 0.061 11 0 0 4.49 0.034 0.144 26 0.431 78 0.425 77 24.67 < 0.0001 0.464 84 0.414 75 0.122 22 38.60 < 0.0001
Male 0.936 132 0.064 9 0 0 3.29 0.069 0.121 17 0.489 69 0.390 55 16.00 < 0.0001 0.433 61 0.468 66 0.099 14 24.98 < 0.0001
Female 0.963 210 0.037 8 0 0 8.02 0.005 0.170 37 0.450 98 0.381 83 26.33 < 0.0001 0.413 90 0.422 92 0.165 36 38.04 < 0.0001
Controls 0.878 216 0.122 30 0 0 0.053 13 0.293 72 0.654 161 0.760 187 0.203 50 0.037 9
Male 0.870 100 0.130 15 0 0 0.061 7 0.278 32 0.661 76 0.774 89 0.183 21 0.043 5
Female 0.885 116 0.115 15 0 0 0.046 6 0.305 40 0.649 85 0.748 98 0.221 29 0.031 4
f, N, AD, EOAD, LOAD, Controls, and the comparing methods see Tables 1 and 2.
α was set at 0.017 (or 0.003) for each Chi-Square test for trend analysis in overall AD (or AD subgroups), referring to Tables 1 and 2.Behavioral and Brain Functions 2006, 2:13 http://www.behavioralandbrainfunctions.com/content/2/1/13
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that the ε4/ε4 genotype frequency was significantly higher
in EOAD than in LOAD and controls, suggesting that the
ε4/ε4 genotype can significantly reduce the age-of-onset.
This is consistent with findings in other studies [e.g.,
[19]].
We also found that the PPV of the ε4/ε4 genotype was sig-
nificantly higher in females (48.4%) than in males
(28.9%). Although the ε4/ε4 genotype frequency in
female AD cases was significantly higher than in female
controls, we found no significant difference in males.
These results suggest that the ε4/ε4 genotype is a stronger
risk factor for females than for males. This is consistent
with findings from other studies [e.g., [41-43]]. However
since sex distributions were not well matched between
cases and controls, it could also reflect a stratification
effect by sex.
Both the chi-square test for trend and the regression anal-
yses revealed that the risk for AD increased significantly
with the number of ε4 alleles. This is also consistent with
findings from other studies [e.g., [18]]. In addition, we
found that the risk for AD decreased with the number of
ε2 or ε3 alleles. Furthermore, the dose of APOE alleles was
linearly related to LR+. These results are all compatible
with those from our allelewise analyses.
This information is of importance in predicting the devel-
opment of AD in early life. However, not all subjects with
the ε4 allele develop AD, nor do all AD patients carry the
ε4 allele. On the other hand, not all subjects are protected
against AD by the ε2 and ε3 alleles. Therefore, it is impor-
tant to estimate the probability that these allele carriers
will develop AD. We found that the ε4/ε4 genotype had a
PPV of 39.90% and an LR+ of 3.76 for AD. In other words,
a subject carrying two ε4 alleles has a probability of
39.90% to develop AD. In contrast, a subject carrying one
ε4 allele and one ε3 allele has a probability of 28.80% to
develop AD, and a subject carrying one ε4 allele and one
ε2 allele has a probability of 10.82% to develop AD. Based
on the interpretation of LRs+ by Ebell [39], the presence of
APOE  alleles can only mildly change the risk for AD,
despite a highly significant association with AD. This
implies that APOE genotype testing can provide evidence
on whether a subject may develop AD, but it is not suffi-
cient as an independent screening or predictive test for the
diagnosis of AD [44]. Additionally, we found the follow-
ing order for both PPVs and LRs+ of APOE alleles and gen-
otypes with respect to the diagnosis of AD: ε4/ε4 > ε4 >
ε3/ε4 > ε3 > ε2/ε4 > ε3/ε3 > ε2 > ε2/ε3 (see Table 3). This
order shows that: (1) ε4/ε4 > ε4, suggesting that the risk
for AD increases with the number of ε4 alleles; (2) ε4 > ε3/
ε4 and ε3/ε4 > AD population prevalence, suggesting that
the ε3 allele reduces the risk for AD conveyed by the ε4
allele, but the protective effect of ε3 is weaker than the risk
effect of ε4; (3) ε3/ε3 <ε3, suggesting that the protection
against AD increases with the number of ε3 alleles; (4) ε3
>  ε2/ε3 and ε2 > ε2/ε3, suggesting that the protective
effect on AD risk for a genotype containing two protective
alleles is greater than that for a genotype containing only
one of the protective alleles; (5) ε3 > ε2 and ε3/ε3 > ε2/ε3,
suggesting that the ε2 allele is a stronger protective factor
for AD than the ε3 allele, which is reflected in their posi-
tions on the Y axis in the figure depicting the dose effect
(Figure 2); and (6) ε3/ε4 > AD population prevalence, but
ε2/ε3 <ε3/ε3 <ε3 < AD population prevalence, suggesting
that without ε4, the ε3 allele and any genotypes contain-
ing the ε3 allele cannot increase risk for AD, that is, it is ε4,
not ε3, that contributes to the increased risk of AD associ-
ated with the ε3/ε4 genotype. Similarly, the PPV for ε2/ε4
< AD population prevalence (i.e., a protective effect), but
ε4/ε4 > ε4 > ε3/ε4 > AD population prevalence (i.e., a risk
effect), suggesting that without ε2, the ε4 allele and any
genotypes containing the ε4 allele (e.g., ε4/ε4 and ε3/ε4)
do not have a protective effect; it is ε2, not ε4, that results
in the ε2/ε4 genotype having a lower PPV. Taken together,
the order of these effects suggests that ε4 is a dose-
response risk factor for developing AD, ε2 is a dose-
response protective factor, and ε3 is a relatively weaker
dose-response protective factor. These findings are con-
sistent with the results of our allelewise analyses, chi-
square tests for trends, and logistic regression analyses.
There has been debate about whether the presence of a
"bad" allele (i.e., ε4) or of a "good" allele (ε2 or ε3), or
both, contribute to the association between APOE and
AD. The answer to this question is important for the
development of specific therapies for AD [45]. Our results
Dose effects of APOE gene alleles Figure 2
Dose effects of APOE gene alleles. X-axis represents the cop-
ies of alleles (ε2 allele, pink line; ε3 allele, green line; ε4 allele, 
red line); Y-axis represents the positive likelihood ratios of 
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tend to show that both the "bad" allele (ε4) and the
"good" alleles (ε2 and ε3) are involved in the risk for AD,
consistent with codominant inheritance. These findings
are supported by the evidence from studies on the neu-
ropathological processes involved in AD [e.g., [6]].
Noting both the close interaction between the APOE and
the tau proteins and the physical proximity of the Tau and
STH genes, we investigated the correlation between effects
of the APOE and STH gene polymorphisms. We found no
significant interactive effect between these two genes
either in cases or in controls. This finding was consistent
with our regression analysis and the studies by Conrad et
al. [23] and Peplonska et al. [22]. Thus, the APOE gene
affects risk for AD through a pathway independent of the
STH gene polymorphism we queried.
We also found no associations between STH alleles and
AD, even after adjusting for potential confounders,
including age, sex, and family history. Neither the geno-
type analysis nor the gene-dose analysis showed any asso-
ciation. Our results suggest that STH may not be a risk
gene for AD. The initial positive findings by Conrad et al.
[23] may be attributable to sampling bias in the context of
small sample sizes (51 AD cases; 30 healthy controls).
Our sample size (286 AD cases; 197 healthy controls) is
much larger than theirs. Moreover, our negative findings
are in good agreement with many other studies, which
also have much larger sample sizes (e.g., 499 AD cases and
402 controls by Verpillat et al. [25]; 225 AD cases and 144
controls by Streffer et al. [27]; 200 AD cases and 458 con-
trols by Clark et al. [28]; 690 AD families, 903 AD cases
and 320 controls by Oliveira et al. [29]; 100 AD cases and
100 controls by Peplonska et al. [22]). Additionally, the Q
allele frequency (0.867) in controls in the initial study is
similar to both controls and cases in our and the other
negative studies; but the Q allele frequency (0.676) in AD
cases is significantly lower than those in cases and con-
trols in most of the published studies [22,25,27-29]. So
far, there has been only one study [24] reporting a repli-
cated positive finding between the genotype STH RR and
AD (p = 0.04), but even this positive finding is only nom-
inal and does not survive after Bonferroni correction.
Therefore, we conclude that the STH gene Q7R variation
does not play an important role in the pathology of AD.
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